STOCK TITAN

HeartSciences Inc. Warrant - HSCSW STOCK NEWS

Welcome to our dedicated page for HeartSciences Warrant news (Ticker: HSCSW), a resource for investors and traders seeking the latest updates and insights on HeartSciences Warrant stock.

Heart Test Laboratories Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The company aims to enhance healthcare by making cardiac screening more valuable, especially in frontline clinical settings.

Rhea-AI Summary
HeartSciences reports Q1 fiscal 2024 business update and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
HeartSciences CEO to participate in Gilmartin Group Emerging Growth Showcase on Sept. 21, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences acquisition
-
Rhea-AI Summary
HeartSciences named Electrocardiography Advancement Specialists of the Year 2023 - USA in the GHP Global Excellence Awards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
HeartSciences extends distribution channel through new agreement with MedPhy Technologies in India.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
HeartSciences signs distribution agreement with FJ Medical for Nordic countries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
HeartSciences' MyoVista wavECGTM selected for heart screening evaluation study in Ireland, potentially leading to national rollout
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
HeartSciences, an AI-based medical technology company, has been issued a notice of patent allowance from the European Patent Office. The patent covers quantification by an ECG of key echocardiographic measures of heart function using AI methods. HeartSciences has been granted or allowed 41 patents, including 9 in the United States, and has international coverage across key countries. The addition of cardiac dysfunction detection to the ECG is expected to provide significant benefit to healthcare providers and health systems worldwide. The company's MyoVista® could play a significant role in heart health screening globally. The patent further expands HeartSciences' extensive patent portfolio, providing a major competitive advantage as they move toward commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
HeartSciences announces that its MyoVista wavECG has been selected for commercial use in clinical practice by the Naya Imaging Center in Denmark. The center will provide cardiac testing using MyoVista, focusing on preventative screening and diagnostics. The MyoVistas in Denmark are prior device versions covered by CE mark, and the company intends to update the CE mark under the new EU Medical Device Regulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
HeartSciences, an AI-based medical technology company, provided a business update and reported financial results for the fiscal year ended April 30, 2023. Key milestones include completing patient enrollment for the MyoVista wavECG multi-center pivotal study, expanding the IP portfolio, receiving patents for AI and key aspects of MyoVista Technology, and entering into a collaboration with Rutgers University for AI ECG algorithm development. The American Medical Association issued new reimbursement codes for AI ECG risk assessment. The company also strengthened its balance sheet and board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
HeartSciences, an AI-based medical technology company, has been recognized as a top healthcare artificial intelligence solutions provider by Healthcare Tech Outlook Magazine. The recognition highlights the company's MyoVista device, which uses AI to transform ECGs/EKGs for earlier detection of heart disease. The company recently completed patient enrollment for its FDA pivotal study and plans to make an FDA submission later this year. HeartSciences aims to become a fixture in frontline healthcare to help physicians make better referral decisions for at-risk patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of HeartSciences Warrant (HSCSW)?

The current stock price of HeartSciences Warrant (HSCSW) is $0.04 as of December 18, 2024.

What is Heart Test Laboratories Inc known for?

Heart Test Laboratories Inc is known for its AI-powered medical technology that transforms ECGs/EKGs to enable earlier detection of heart disease.

What is the primary objective of Heart Test Laboratories Inc?

The primary objective of Heart Test Laboratories Inc is to improve healthcare by making cardiac screening a more valuable tool in frontline or point-of-care clinical settings.

What recent achievement has Heart Test Laboratories Inc had?

Heart Test Laboratories Inc demonstrated that its MyoVista AI-ECG model outperformed conventional screening standards for Stage B Heart Failure.

What is the focus of Heart Test Laboratories Inc's technology?

The focus of Heart Test Laboratories Inc's technology is on utilizing AI to enhance ECG/EKG screenings for the early detection of heart conditions.

What recent patent did Heart Test Laboratories Inc receive?

Heart Test Laboratories Inc was granted an Indian Patent for its MyoVista® Wavelet Technology, affirming its commitment to innovation in heart disease detection.

HeartSciences Inc. Warrant

Nasdaq:HSCSW

HSCSW Rankings

HSCSW Stock Data

950.00k
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
SOUTHLAKE